Thermo Fisher Scientific Inc. $TMO Shares Bought by Trexquant Investment LP

Key Points

• Trexquant Investment LP significantly increased its stake in Thermo Fisher Scientific by 2,638.9%, now owning 34,181 shares valued at approximately $17 million.
• Institutional investors now hold 89.23% of Thermo Fisher's stock, with several other firms also increasing their stakes in recent quarters.
• Thermo Fisher recently declared a quarterly dividend of $0.43 per share, representing an annualized yield of 0.4%, set to be paid on October 15th.

Trexquant Investment LP increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2,638.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 34,181 shares of the medical research company's stock after buying an additional 32,933 shares during the period. Trexquant Investment LP's holdings in Thermo Fisher Scientific were worth $17,008,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Okabena Investment Services Inc. lifted its holdings in shares of Thermo Fisher Scientific by 1.7% in the 1st quarter. Okabena Investment Services Inc. now owns 4,086 shares of the medical research company's stock worth $2,033,000 after acquiring an additional 67 shares during the last quarter. Wealth Preservation Advisors LLC purchased a new position in Thermo Fisher Scientific during the 1st quarter valued at $73,000. B. Metzler seel. Sohn & Co. AG increased its position in Thermo Fisher Scientific by 45.9% during the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 591,068 shares of the medical research company's stock valued at $294,115,000 after purchasing an additional 185,870 shares during the period. Guggenheim Capital LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.5% during the 1st quarter. Guggenheim Capital LLC now owns 42,462 shares of the medical research company's stock valued at $21,129,000 after buying an additional 1,841 shares in the last quarter. Finally, Ieq Capital LLC boosted its holdings in shares of Thermo Fisher Scientific by 15.6% during the 1st quarter. Ieq Capital LLC now owns 42,969 shares of the medical research company's stock valued at $21,381,000 after buying an additional 5,798 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded down $6.08 during midday trading on Tuesday, hitting $486.64. The stock had a trading volume of 871,410 shares, compared to its average volume of 2,437,594. The firm's fifty day moving average is $454.36 and its two-hundred day moving average is $453.50. The company has a market capitalization of $183.76 billion, a PE ratio of 28.16, a P/E/G ratio of 2.63 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the firm posted $5.37 EPS. The company's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Analyst Ratings Changes

A number of brokerages have recently commented on TMO. William Blair began coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating on the stock. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a research note on Friday, July 11th. Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, UBS Group upped their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Insider Activity

In related news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,896 shares of company stock worth $13,603,438 in the last quarter. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.